Dataset Information

[COVID-19: retrospective analysis of cardiac surgery capacity in German heart centers].

ABSTRACT:

Background

For documentation of COVID-19 pandemic-related changes in cardiac surgery in Germany, the German Society for Thoracic and Cardiovascular Surgery carried out a structured survey.

Methods

From 79 German institutions for cardiac surgery, 53 took part in the survey. The cut-off date before the pandemic was taken as 1 January 2020 and 30 April 2021 as the cut-off date for data recruitment. At this point of time, the third wave of the pandemic in Germany had already ebbed away and the return to routine surgery seemed to be foreseeable.

Results

On 1 January 2020, in 53 German cardiac surgery departments 800 intensive care beds were allocated. In April 2021, this capacity was reduced by 25.6% to 595 beds. Accordingly, the number of operating rooms for cardiac surgery procedures was reduced from 207 to 152 (-26.9%) during the first two lockdowns. During the COVID-19 pandemic, hospital facilities were restructured: 50.9% of participants delegated medical personnel, and 75.5% had to transfer nursing personnel to special COVID-19 facilities in their hospitals.

Conclusion

From the start of the COVID-19 pandemic until the end of the third wave during April 2021, cardiac surgery in Germany changed profoundly, leading to a substantial reduction of intensive care beds and operating rooms for patients requiring cardiac surgery.

SUBMITTER: Boning A

PROVIDER: S-EPMC9362024 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

[COVID-19: retrospective analysis of cardiac surgery capacity in German heart centers].

Böning Andreas A Falk Volkmar V Gummert Jan J Markewitz Andreas A Heinemann Markus M Beckmann Andreas A

Zeitschrift fur Herz-, Thorax- und Gefasschirurgie 20220803 5

<h4>Background</h4>For documentation of COVID-19 pandemic-related changes in cardiac surgery in Germany, the German Society for Thoracic and Cardiovascular Surgery carried out a structured survey.<h4>Methods</h4>From 79 German institutions for cardiac surgery, 53 took part in the survey. The cut-off date before the pandemic was taken as 1 January 2020 and 30 April 2021 as the cut-off date for data recruitment. At this point of time, the third wave of the pandemic in Germany had already ebbed awa ...[more]

PMID: 35968031

Similar Datasets

Project description:ObjectiveTo evaluate the success of initiation of adjunctive brivaracetam in patients who required a change in antiepileptic drug (AED) regimen and substituted at least one AED with brivaracetam.MethodsIn this retrospective noninterventional study conducted in specialized epilepsy centers across Germany, patients initiated adjunctive brivaracetam between February 15, 2016, and August 31, 2016, as part of an intended change in AED regimen. The primary effectiveness variable was the proportion of patients who continued on brivaracetam after 3 months, and withdrew at least one AED either before or within 6 months after brivaracetam initiation.ResultsFive hundred and six patients had at least one brivaracetam dose and were included in the safety set (SS). Four hundred and seventy patients started to reduce the dose of one AED before/after brivaracetam initiation, had at least one concomitant AED at brivaracetam initiation, and were included in the full analysis set (FAS) for effectiveness analyses. At baseline, patients had a median of seven lifetime AEDs and a median of 3.8 seizures/28 days. In the SS, 85.2% of patients withdrew one AED before/after initiation of brivaracetam, most commonly levetiracetam (49.4%). 46.2% of patients substituted another AED with brivaracetam within 24 hours (fast withdrawal). The proportions of patients (FAS) who continued on brivaracetam after 3 and 6 months and withdrew one AED were 75.5% and 46.6%, respectively. After 6 months, 32.1% of patients were 50% responders; 13.0% were seizure-free. In the SS, 34.6% of patients reported treatment-emergent adverse events (TEAEs); 21.9% had TEAEs that were assessed by the treating physician as drug-related. Incidences of behavioral AEs before (3-month baseline) and after brivaracetam initiation in patients who withdrew levetiracetam were 19.2% and 8.0%, respectively (5.0% and 7.7% in patients who withdrew other AEDs).SignificanceBrivaracetam was effective and well-tolerated in patients who required a change in AED drug regimen and initiated adjunctive brivaracetam in German clinical practice.

Dataset Information

[COVID-19: retrospective analysis of cardiac surgery capacity in German heart centers].

Background

Methods

Results

Conclusion

Publications

[COVID-19: retrospective analysis of cardiac surgery capacity in German heart centers].

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets